Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, Antoni; Hamid, Omid; Daud, Adil; Stephen Hodi, F.; D. Wolchok, Jedd; Kefford, Richard; M. Joshua, Anthony; Patnaik, Amita; Hwu, Wen-Jen; S. Weber, Jeffrey; C. Gangadhar, Tara; Hersey, Peter; Dronca, Roxana; W. Joseph, Richard; M. Zarour, Hassane; Chmielowski, Bartosz; P. Lawrence, Donald; P. Algazi, Alain; A. Rizvi, Naiyer; Hoffner, Brianna; Mateus, Christine; Gergich, Kevin; A. Lindia, Jill; Giannotti, Maxine; Li, Xiaoyun; Ebbinghaus, Scot; Peter Kang, Soonmo; Robert, Caroline

doi:10.1001/jama.2016.4059

Public

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Published in JAMA • Apr 19, 2016

Authors:

Antoni Ribas

Omid Hamid

Adil Daud

Abstract

IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced m...

Subject

Medicine

Ipilimumab

Pembrolizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!